Skip Navigation



JAC Advance Access published online on May 2, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl173
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
58/1/117    most recent
dkl173v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sriskandan, S.
Right arrow Articles by Cohen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sriskandan, S.
Right arrow Articles by Cohen, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received December 29, 2005
Revised March 30, 2006
Accepted April 9, 2006

Original article

Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation

Shiranee Sriskandan 1 *, Melissa Ferguson 1 {dagger}, Victoria Elliot 2, Lee Faulkner 1, and Jonathan Cohen 1 {ddagger}

1 Department of Infectious Diseases, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK
2 Department of Histopathology, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

* To whom correspondence should be addressed.
Shiranee Sriskandan, E-mail: s.sriskandan{at}imperial.ac.uk


  Abstract

Objectives: Polyclonal human intravenous immunoglobulin (IVIG) has been advocated as an adjunct to therapy in severe invasive streptococcal toxic shock because of its ability to neutralize superantigen toxins. The aim of this study was to assess IVIG therapeutic efficacy in an experimental model of streptococcal toxic shock.

Methods: To confirm the in vitro activity of IVIG against the Streptococcus pyogenes strain used in the study, IVIG was tested for superantigen neutralizing and bacterial opsonizing activity prior to in vivo studies. To evaluate the in vivo effects of IVIG in terms of microbiological outcome and disease severity in a superantigen-sensitive transgenic model of streptococcal shock, HLA-DQ transgenic mice were treated with IVIG either at the time of infection or after infection with S. pyogenes. Antibiotics were included in some studies.

Results: The IVIG preparation neutralized superantigenicity of S. pyogenes in vitro and enhanced bacterial killing in a whole blood assay. When given to mice at the time of S. pyogenes infection, IVIG neutralized circulating superantigens and reduced systemic inflammatory response. Remarkably, IVIG-enhanced systemic clearance of bacteria and enhanced neutrophil infiltrate into the infected tissues. However, when used in combination with penicillin and clindamycin in a delayed treatment setting, IVIG did not confer additional therapeutic benefit, in terms of inflammatory response, bacterial clearance or survival.

Conclusions: IVIG monotherapy can confer benefit in experimental streptococcal shock, but extension of these findings to the clinical situation will require further evaluation.

Keywords: Streptococcus pyogenes; polyclonal immunoglobulin; septic shock; superantigen.

{dagger}Present address. Children's Hospital, Royal Melbourne Hospital, Parkville, Victoria 3050, Australia

{ddagger}Present address. Dean, Brighton & Sussex Medical School, Medical School Building, University of Sussex, Falmer BN1 9PX, UK


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Trop DoctHome page
L. Doganci, E. Tanyel, H. Basibuyuk, and O. Darka
A fatal case of streptococcal toxic shock syndrome
Trop Doct, April 1, 2008; 38(2): 129 - 131.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. M. Nooh, N. El-Gengehi, R. Kansal, C. S. David, and M. Kotb
HLA Transgenic Mice Provide Evidence for a Direct and Dominant Role of HLA Class II Variation in Modulating the Severity of Streptococcal Sepsis
J. Immunol., March 1, 2007; 178(5): 3076 - 3083.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Sriskandan
Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation--author's response
J. Antimicrob. Chemother., January 1, 2007; 59(1): 159 - 160.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
G. Rajagopalan, R. Patel, S. V. Kaveri, and C. S. David
Comment on: Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation
J. Antimicrob. Chemother., January 1, 2007; 59(1): 157 - 159.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.